{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:34:26Z","timestamp":1788885266954,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,1,31]],"date-time":"2007-01-31T00:00:00Z","timestamp":1170201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Anti\u2010tumour necrosis factor\u2010<jats:italic>\u03b1<\/jats:italic> antibodies are useful for the treatment of refractory Crohn's disease and ulcerative colitis. Thalidomide is another agent with tumour necrosis factor\u2010<jats:italic>\u03b1<\/jats:italic> suppressive properties.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the long\u2010term efficacy and safety of thalidomide in a group of children and young adults with refractory inflammatory bowel disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty\u2010eight patients with refractory moderate\u2010severe inflammatory bowel disease (19 Crohn's disease, 9 ulcerative colitis) received thalidomide 1.5\u20132.5\u2003mg\/kg\/day. Patients were assessed at baseline, at weeks 2, 4, 8 and 12, and then every 12\u2003weeks by patient's diary, physical examinations, laboratory analyses and scoring on activity indexes. Primary outcomes were: (i) efficacy in inducing remission; and (ii) efficacy in maintaining remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Remission was achieved with thalidomide in 21 of 28 (75%) patients (17 with Crohn's disease, 4 with ulcerative colitis). Mean duration of remission was 34.5\u2003months. Sixteen of 20 (80%) patients suspended steroids. Reversible neuropathy occurred in seven of 28 (25%) patients, but only with cumulative doses over 28\u2003g. Other side effects requiring thalidomide suspension were vertigo\/somnolence (one of 28), and agitation\/hallucinations (one of 28).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Thalidomide seems to be effective in inducing long\u2010term remission in children and adolescents with intractable inflammatory bowel disease. Neuropathy is the main adverse effect, but appears to be cumulative dose\u2010dependent, thus allowing long\u2010term remission before drug suspension.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2006.03211.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T10:47:28Z","timestamp":1279882048000},"page":"419-427","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long\u2010term results"],"prefix":"10.1111","volume":"25","author":[{"given":"M.","family":"LAZZERINI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"MARTELOSSI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"MARCHETTI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"SCABAR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"BRADASCHIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"RONFANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"VENTURA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,31]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199903000-00010"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.2.203"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.4.443"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90999-J"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.12.1705"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16308-3"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A098"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.3.699"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2478(99)00055-3"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.6.1675"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100938200"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb05527.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(98)00010-1"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.2.196"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200606000-00012"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15952-7"},{"key":"e_1_2_8_21_2","first-page":"1429","article-title":"Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy","volume":"27","author":"Ordi\u2010Ros J","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1983.tb04600.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archderm.1990.01670310085012","article-title":"Crossover study of thalidomide vs. placebo in severe recurrent aphthous stomatitis","volume":"126","author":"Revuz J","year":"1990","journal-title":"Arch Dermatol"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705223362103"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/515222"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-6-199803150-00004"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.8.933"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.103.4.e44"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70276-3"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70277-5"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2002.02564.x"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200310000-00023"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200102000-00016"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(76)80163-1"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000183350.46795.42"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.70.830.901"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690010070009"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00192350"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.19502.x"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000037480.59194.85"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.12.2291"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200502000-00035"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.03211.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.03211.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:50:26Z","timestamp":1697230226000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.03211.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,31]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1111\/j.1365-2036.2006.03211.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03211.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,31]]}}}